{"entity":{"id":"paper-checkmate-743-lancet-2021","kind":"paper","name":"CheckMate 743: first-line nivolumab plus ipilimumab in unresectable pleural mesothelioma","aka":[],"tldr":"Dual immunotherapy with nivolumab and ipilimumab lengthened survival compared with platinum-pemetrexed chemotherapy in pleural mesothelioma, the first improvement in first-line treatment in almost twenty years, with the largest gain in non-epithelioid tumours.","summary":"Phase 3 trial of 605 patients with untreated unresectable malignant pleural mesothelioma randomised to nivolumab plus ipilimumab or platinum plus pemetrexed.\n\nMedian overall survival was 18.1 versus 14.1 months (hazard ratio 0.74); in non-epithelioid histology it was 18.1 versus 8.8 months (hazard ratio 0.46), while the difference in epithelioid disease was small. Three-year survival was 23 versus 15 percent.","asOf":"2026-09-17","links":[{"label":"Lancet 2021","url":"https://doi.org/10.1016/S0140-6736(20)32714-8"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/33485464/"}],"tags":[],"related":[],"cancers":["pleural-mesothelioma","peritoneal-mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":["ipilimumab","nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["checkmate-743"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet"],"dependsOn":[],"notes":[],"journal":"The Lancet","year":2021,"doi":"10.1016/S0140-6736(20)32714-8","pmid":"33485464","authors":"Baas P, Scherpereel A, Nowak AK, et al.","paperType":"rct","findings":["Median overall survival 18.1 vs 14.1 months; hazard ratio 0.74.","Non-epithelioid: 18.1 vs 8.8 months; hazard ratio 0.46."],"whatItMeans":"Nivolumab-ipilimumab is the preferred first-line treatment for non-epithelioid pleural mesothelioma and an option in epithelioid disease alongside chemo-immunotherapy.","caveats":["Open-label; early crossing of survival curves indicates some patients do worse without chemotherapy.","Epithelioid benefit was modest."],"changedPractice":true,"participants":605},"route":"/key-papers/paper-checkmate-743-lancet-2021/","neighbours":{"cancer":[{"id":"peritoneal-mesothelioma","kind":"cancer","name":"Peritoneal mesothelioma","route":"/cancers/peritoneal-mesothelioma/"},{"id":"pleural-mesothelioma","kind":"cancer","name":"Pleural mesothelioma","route":"/cancers/pleural-mesothelioma/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"trial":[{"id":"checkmate-743","kind":"trial","name":"CheckMate 743","route":"/trials/checkmate-743/"}],"journal":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/"}]}}